Development Center for Biotechnology

Shu-Bin Lu

David Chen

Pao-Nien Chen

Fan-Jung Liu

Wen-Pao Tseng

Chuan-Ming Lai

Rong-Jer Tsay

Hui-Fang Chang

Hue-In Lin

Shouchung Chao

Shu-Jian Liu

The present invention provides sustained release oral solid dosage forms of cisapride by using a multi-particulate system, which are bioavailable and can provide efficient blood level of cisapride over 24 hours. Unit dosage forms of cisapride which comprise a plurality of substrates containing sustained release cisapride, as well as pharmaceutical compositions containing the dosage forms, are also disclosed herein.

Oral cisapride dosage forms with an extended duration

Controlled release tacrine dosage form

A stable solid dispersion of prostaglandin drug, particularly Misoprostol, (.+-.)methyl 7-�3(.alpha.)-hydroxy-2-.beta.-(4 (RS)-4-hydroxy-4-methyl-trans-1-octen-1-yl)-oxycyclopent-1.alpha.-yl!hepta noate, comprising ammonio methacrylate copolymers. The ammonio methacrylate copolymers comprise Eudragit RS series, Eudragit RL series, Eudragit S, Eudragit L, and the mixture thereof. The stable solid dispersion is a sustained release type.

Stabilization of prostaglandin drug

Growing community of inventors

Taipei, Taiwan

Shu-Bin Lu